

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Not applicable	<p>A study in mice suggests antioxidants could help treat cancer by stopping the suppression of the immune system by myeloid-derived suppressor (MDS) cells. Mice fed the antioxidant bardoxolone methyl had less MDS cell activity and smaller tumor size after adoptive T cell transfer than control mice fed regular chow. Next steps include clinical development of bardoxolone methyl as an adjunct to cellular immunotherapy.</p> <p>Reata Pharmaceuticals Inc. and partners Abbott Laboratories and Kyowa Hakko Kirin Co. Ltd. have RTA 402 bardoxolone methyl in Phase III testing for renal disease and Phase I testing for diabetic nephropathy.</p> <p>SciBX 4(47); doi:10.1038/scibx.2011.1319 Published online Dec. 8, 2011</p>	Unpatented; licensing status not applicable	<p>Lu, T. <i>et al. J. Clin. Invest.</i>; published online Sept. 12, 2011; doi:10.1172/JCI45862</p> <p>Contact: Dmitry Gabrilovich, H. Lee Moffitt Cancer Center, Tampa, Fla. e-mail: dmitry.gabrilovich@moffitt.org</p>